| Code | CSB-RA004888MB7HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to inebilizumab-cdon, targeting the CD19 antigen expressed on B cells throughout their development from pre-B cells to plasma cells. CD19 functions as a critical B cell co-receptor that modulates B cell receptor signaling, lowering the threshold for antigen-mediated activation and proliferation. This transmembrane protein plays essential roles in B cell development, immune response regulation, and antibody production. Aberrant CD19 expression and B cell dysfunction are implicated in various autoimmune disorders, B cell malignancies including acute lymphoblastic leukemia and non-Hodgkin lymphoma, and neuromyelitis optica spectrum disorders.
Inebilizumab-cdon is a humanized IgG1 kappa monoclonal antibody that binds to CD19 and mediates B cell depletion through antibody-dependent cellular cytotoxicity. This biosimilar antibody serves as a valuable research tool for investigating B cell biology, exploring mechanisms of B cell-mediated pathology, and studying potential therapeutic interventions in autoimmune and hematological conditions. It enables researchers to examine CD19-targeted depletion strategies and B cell signaling pathways in preclinical models.
There are currently no reviews for this product.